top of page
  • Writer's pictureEscalate Life Sciences

Eli Lilly Releasing Cheaper Insulin Generic to Compete With Lispro Products

Eli Lilly's introducing lower-priced generic versions of its most popular insulin products


Eli Lilly (NYSE:LLY) took another big swipe at America's rebate-hungry reimbursement system by launching a generic competitor for two more of its popular insulin lispro containing products. 

Diabetes patients that want to manage their blood sugar levels with Humalog Mix 75/25 or Humalog Junior will have a new less expensive option. Eli Lilly will offer generic versions of both insulin-lispro containing brands.

Wider margins at half the price

A five-pack of Insulin Lispro Protamine injector pens will have a list price set at $265.20, which is less than half as much as the identical product branded as Humalog Mix75/25. Despite the steep discount, Eli Lilly will probably record more net revenue from each pen sold as a generic.

Insurers and healthcare plan sponsors have a bottomless appetite for rebates and discounts that they don't always share with their customers. The gap between list prices Eli Lilly raises each year and the amount the company records as net revenue has finally reached a breaking point.

Written by: Cory Renauer (TMFang4apples)

Published on: Jan 14, 2020 at 11:46AM

0 views0 comments
bottom of page